Biogen Idec and Abbott Company Profile
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the worldâs oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.
News Articles
Return to top bigbiotech list Summary Website: Biogen Headquarters: Massachusetts, USA Ticker Symbol: BIIB (Nasdaq Stock Exchange) IDP (Frankfurt Stock Exchange) SEC Link: Biogen Subsidiaries: Bi...
Biogen Says Its FDA Delay Unrelated To Abbott’s Failed Medicine
Shares in Biogen Idec dipped 2.7% not only because the Food and Drug Administration said it would take an extra three months to review its key multiple sclerosis drug, BG-12, but because an Abbott Lab...
– More than 50 Company- and Partner-Sponsored Presentations from the Biogen Idec MS Franchise and Pipeline to be Presented at the MS Community's Largest Medical Meeting – Biogen Idec (NASDAQ: BIIB...
Biogen Idec, Eisai Team Up At Research Triangle Park Facilities
WESTON (dpa-AFX) - Biogen Idec Inc.(BIIB) and Eisai Inc. Wednesday announced that they have entered into an agreement pursuant to which Biogen Idec is expected to lease a portion of the Eisai Rese...
Deciding to bet on dexpramipexole, an experimental drug for ALS, was one of the first bets made by Biogen Idec chief executive George Scangos when he arrived at the company. Now the medicine has faile...
Biogen Idec awards $100,000 to launch STEM education collaboration with Teach for America
The Biogen Idec Foundation and Teach For America announced a new collaboration in support of Science, Technology, Engineering, and Math (STEM) education. A $100,000 grant from The Biogen Idec Foundati...
Biogen Idec enters into a pact with Regulus Therapeutics to monitor MS
Regulus Therapeutics has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis. Under the transaction, Biogen Idec will make an investment in Regulus...
Biogen Idec sells benlysta royalty rights to DRI Capital
Biogen Idec and DRI Capital has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with H...
Drugs and Medications
Oxygen [Abbott Welding Supply]
Oxygen Compressed Label
Androgel [Abbott Products, Inc.]
These highlights do not include all the information needed to use ANDROGEL 1.62% safely and effectively. See full prescribing information for ANDROGEL 1.62%.AndroGel (testosterone gel) 1.62% for topic...
AVONEX (Interferon beta-1a)IM Injection
AVONEX (Interferon beta-1a)IM Injection
These highlights do not include all the information needed to use ACEON safely and effectively. See full prescribing information for ACEON.ACEON (perindopril erbumine) 2, 4 and 8 mg Tablets Initial U....
PubMed Articles
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated with the JC virus. W...
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of th...
Natalizumab and HSV meningitis.
Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease....
Separation of nonfucosylated antibodies with immobilized FcγRIII receptors.
Post-translational modifications can dramatically impact protein activity, but identifying such structure:function relationships, as well as capitalizing on functionally enhanced variants, is a signif...
Design of next-generation protein therapeutics.
Since the first protein therapeutics were approved two decades ago, the field has seen a transition from the development of naturally occurring proteins to design of molecules engineered for optimal t...
Clinical Trials
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is...
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...
Pregnancy Exposure Registry for AVONEX
This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...
Companies
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in...
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...
Biogen Idec and Elan Corporation, plc
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...
Biogen Idec and Portola Pharmaceuticals
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in...
Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more t...
More Information about "Biogen Idec and Abbott" on BioPortfolio
We have published hundreds of Biogen Idec and Abbott news stories on BioPortfolio along with dozens of Biogen Idec and Abbott Clinical Trials and PubMed Articles about Biogen Idec and Abbott for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Idec and Abbott Companies in our database. You can also find out about relevant Biogen Idec and Abbott Drugs and Medications on this site too.
